Louisiana
Prescription drug spending and prescribing in Louisiana, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $4.8B for prescriptions written in Louisiana, the 23rd most of 52 states and territories, and 4.2% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $4.8B
- Medicaid drugs, 2025: $2.5B
- Opioid share of claims: 4.2%
- Life-science raises, 2 years: $66M
Opioid share of Part D claims, 2024
Louisiana outlined; every state in quartiles. Click a state to compare.
- Up to 3.2%
- 3.2% to 3.7%
- 3.7% to 4.3%
- Over 4.3%
| Share of Part D claims | Louisiana | United States | Difference |
|---|---|---|---|
| Opioids | 4.2% | 3.5% | +19% |
| Antibiotics | 4.2% | 4.4% | −5% |
| Antipsychotics | 1.7% | 1.7% | −3% |
| Drug | Against national rate | Claims |
|---|---|---|
| Cyproheptadine HCl | 5.8× | 23,484 |
| Levocetirizine dihydrochloride | 2.5× | 101,269 |
| Megestrol acetate | 2.2× | 18,847 |
| Butalb/acetaminophen/caffeine | 2.1× | 29,092 |
| Propafenone HCl | 2.0× | 9,445 |
| Tirzepatide | 2.0× | 179,182 |
| Hydroxyzine pamoate | 2.0× | 54,977 |
| Methocarbamol | 2.0× | 110,587 |
| Linaclotide | 1.9× | 86,143 |
| Promethazine HCl | 1.9× | 45,277 |
- Nest Healthcare, Inc.$23M · Other health care · Aug 25, 2025
- Starget Pharma Inc.$16M · Biotech · Feb 3, 2026
- AxoSim, Inc.$8.5M · Biotech · Jun 24, 2025
- Royal & Pelham, Inc.$5.4M · Health insurance · Sep 15, 2026
- AxoSim, Inc.$3.7M · Biotech · Nov 22, 2024
- Wavegate Corp$2.8M · Other health care · Jun 6, 2025
- QUICKTAKE HEALTH CO$2.1M · Biotech · Aug 6, 2026
- Therapeutic Neuromodulation Systems LLC$1.7M · Biotech · Sep 21, 2026
- Care Eleven Performance Holdings, LLC$1.2M · Other health care · Feb 24, 2026
- Therapeutic Neuromodulation Systems LLC$970K · Biotech · Sep 11, 2026
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- Louisiana v. Amgen, No. 08-0373 (Louisiana, Civ. Dist. Ct. for Parish of Orleans, 2009)2009 · Dismissed
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG